Neuropsychiatry of the basal ganglia

Journal of Neurology Neurosurgery and Psychiatry

Volumn 72, Issue 1, 2002, Pages 12-21

  Ring, H A ^a,b   Serra Mestres, J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATTENTION; BASAL GANGLION; BRAIN REGION; EMOTION; MENTAL HEALTH; MOTOR PERFORMANCE; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; REWARD;

EID: 0036145199     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.72.1.12     Document Type: Review

References (133)

1. Basal ganglia
2. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems
3. Parallel organisation of functionally segregated circuits linking basal ganglia and cortex
4. New concepts about the organisation of basal ganglia output
5. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive functions
6. Anatomical basis for basal ganglia involvement in working memory
7. Neuronal activity in the basal ganglia. Functional implications
8. The current model of basal ganglia organisation under scrutiny
9. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organisation of the striatum
10. Synaptic transmission in the striatum: From plasticity to neurodegeneration
11. Cortical mal-development antipsychotic drugs and schizophrenia: A search for common ground
12. Basal ganglia-thalamocortico circuits: Parallel substraits for motor, occular-motor prefrontal and limbic functions
13. Neurotransmitters and neuromodulators in the basal ganglia
14. Neuroimaging and neuropsychology of the striatum. Bridging basic science and clinical practice
15. Reward prediction in primate basal ganglia and frontal cortex
16. Neuro behavioural mechanisms of reward and motivation
17. The epidemiology of Parkinson's disease
18. Psychiatric morbidity in patients with Parkinson's disease
19. Range of neuropsychiatric disturbances in patients with Parkinson's disease
20. Depression in Parkinson's disease: A review
21. Depression in Parkinson's disease
22. Depression in Parkinson's disease: A biochemical and organic viewpoint
23. Psychiatric symptoms in parkinsonism
24. Vulnerability to emotionally negative stimuli in Parkinson's disease: An investigation using the emotional Stroop task
25. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort
26. A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson's disease
27. Cognitive impairments and depression in Parkinson's disease: A follow up study
28. Depression in Parkinson's disease
29. Parkinson's disease and depression: A critical re-evaluation
30. Cognitive disturbances in parkinsonian patients with depression
31. Antecedent clinical features associated with dementia in Parkinson's disease
32. Psychiatric side effects of levodopa in man
33. Psychosis and other psychiatric manifestations of levodopa therapy
34. Parkinson's disease and anxiety: Co-morbidity with depression
35. Brodyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: An experimental study
36. Psychoses in Parkinson's disease
37. Pharmacology of hallucinations induced by long-term drug therapy
38. Parkinson's disease and parkinsonism
39. Drug abuse: Hedonic homeostatic dysregulation
40. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
41. The neuropsychology of Parkinson's disease
42. Managing the neuropsychiatric symptoms of Parkinson's disease
43. Frequency of dementia in Parkinson's disease
44. Risk factors for dementia in Parkinson's disease: Effect of education
45. The frequency and associated risk factors for dementia in patients with Parkinson's disease
46. Dementia in Parkinson's disease
47. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease: A consecutive series of eight simultaneous bilateral and 12 unilateral procedures
48. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease
49. A study of medial pallidotomy for Parkinson's disease: Clinical outcome, MRI location and complications
50. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease
51. Cognitive function in patients with Parkinson's disease undergoing stereotaxic thalamotomy
52. Unilateral pallidal stimulation for Parkinson's disease: Neurobehavioral functioning before and 3 months after electrode implantation
53. Depression in patients with Parkinson's disease
54. Electroconvulsive therapy in Parkinson's disease and other movement disorders
55. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease
56. Olanzapine in the treatment of dapaminomimetic psychosis in patients with Parkinson's disease
57. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
58. Huntington's disease in Maryland: Clinical aspects of racial variation
59. Neuropsychiatic aspects of Huntington's disease
60. Huntington's disease
61. The association of affective disorder with Huntington's disease in a case series and in families
62. Neuropsychiatry of Huntington's disease and other basal ganglia disorders
63. Increased risk of suicide among patients with Huntington's disease
64. Depression in Huntington's disease
65. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease
66. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease
67. Crime in Huntington's disease: A study of registered offences among patients relatives and controls
68. Cognitive manifestations of Huntington's disease in relation to genetic structure and clinical onset
69. Obsessive-compulsive disorder in Huntington's disease
70. Prevalence and natural history of progressive supranuclear palsy
71. The clinical features of 67 patients with clinically definite Steele-Richardson-Olszewski syndrome
72. Haplotype and mutation analysis in Japanese patients with Wilson's disease
73. Wislon's disease (progressive hepatolenticular degeneration)
74. Psychiatric and behavioral abnormalities in Wilson's disease
75. Wilson's disease: Psychiatric symptoms in 195 cases
76. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: A review of the literature and overview of research opportunities in Huntington's, Wilson's disease, and Fahr's diseases
77. Wilson's disease: A longitudinal study of psychiatric symptoms
78. Psychopathological alterations in cases of symmetrical basal ganglia sclerosis
79. Identification of a locus on chromosome 14q for idiopathic basal ganglia calcification (Fohr disease)
80. Annotation: Gilles de la Tourette syndrome: An update
81. Tic disorders: New developments in Tourette syndrome and related disorders
82. Tourette syndrome, associated conditions and the complexities of treatment
83. Sex of parent transmission effect in Tourette's syndrome: Evidence for earlier age at onset in maternally transmitted cases suggests a genomic imprinting effect
84. PET studies of the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome
85. Dopamine receptor availability in Tourette's syndrome
86. PET studies of the pre and pastsynaptic dopaminergic system in Tourette's syndrome
87. Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus receptor binding
88. Dopamine transporter reuptake sites measured by [11C]WIN 35,428 PET imaging are elevated in Tourette syndrome
89. [1231]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder
90. Tourette's syndrome: [1-123]β-CIT SPECT correlates of vocal tic severity
91. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome
92. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome
93. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder
94. Reduced caudate volume in obsessive compulsive disorder
95. Increased right caudate nucleus size in obsessive compulsive disorder: Detection and magnetic resonance imaging
96. Systematic changes in cerebal glucose metabolic rate after successful behaviour modification treatment of obsessive compulsive disorder
97. Functional magnetic resonance imaging or symptom provocation in obsessive compulsive disorder
98. Tourette's and comorbid syndromes: Obsessive compulsive and attention deficit hyperactivity disorder. A common aetiology?
99. An MRI study of the basal ganglia in autism
100. Regional brain enlarge in autism: A magnetic imaging study
101. Striatal dysfunction in attention deficit and hypokenetic disorder
102. Attention deficit hyperactivity disorder and asymmetric of the caudate nucleus
103. Schizophrenia, psychosis, and the basal ganglia
104. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: A neuropsychological study
105. Prevalence of obsessive-compulsive disorder in schizophrenia and significance of motor symptoms
106. Basal ganglia regional glucose metabolism asymmetry during a catatonic episode
107. The pathomorphology of schizophrenia and mood disorders: Similarities and differences
108. D3 receptors and the actions of neuroleptics in the ventral striapallidal system of schizophrenics
109. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja
110. Induction patents on foss-like immunary activity in the forebrain as predictors of atypical antipsychotic activities
111. Identification of the neural systems sub-serving the actions of clozapine: Clues from immediate early gene expression
112. Serotonin dopamine interaction and its relevance to schizophrenia
113. Major depression and the basal ganglia
114. Prefrontal cortical-amygdala metabolism in major depressions
115. Frontaostriatal deficits in unipolar major depression
116. Pre-frontal dysfunction in depressed patients performed a complexed planning task: A study using positron imaging tomography
117. Kindling of musalimbic dopamine system: Animal model psychosis
118. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: Preliminary data from a postmortem study
119. The anatomy of mood disorders: Review of structural neuroimaging studies
120. Cortical magnetic resonance imaging changes in elderly inpatients with major depression
121. Magnetic resonance imaging of basal ganglia in depression
122. Sub-cortical hyperintensitites on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression
123. Striatal dopamine transporter density in major depression
124. From motivation to action: Functional interface between the limbic system and the motor system
125. Associative processes in addition and reward. The role of amygdala-ventral striatal subsystems
126. The role of the striatopallidal and extended amygdala systems in drug addictions
127. Addiction a disease of compulsion and drive: Involvement of the orbitofrontal cortex
128. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behaviour by reward-related stimuli